AstraZeneca: Imfinzi Approved in China for Stage III Nonsmall-Cell Lung Cancer
12 Diciembre 2019 - 01:53AM
Noticias Dow Jones
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Thursday that it has received
marketing authorization from China's national medical products
administration for Imfinzi for the treatment of patients with stage
III nonsmall-cell lung cancer.
The U.K. pharmaceuticals company said approval of Imfinzi is
based on results from the primary analysis of progression-free
survival and supported by overall survival from the Phase III
Pacific trial.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 12, 2019 02:38 ET (07:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024